These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27416882)

  • 41. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
    Li T; Wang B; Wang Z; Ragaz J; Zhang J; Sun S; Cao J; Lv F; Wang L; Zhang S; Ni C; Wu Z; Xie J; Hu X
    PLoS One; 2015; 10(7):e0133133. PubMed ID: 26186012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
    Tampaki EC; Tampakis A; Alifieris CE; Krikelis D; Pazaiti A; Kontos M; Trafalis DT
    Clin Drug Investig; 2018 Jul; 38(7):639-648. PubMed ID: 29744672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
    Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
    Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
    Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
    BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
    Schneeweiss A; Förster F; Tesch H; Aktas B; Gluz O; Geberth M; Hertz-Eichenrode MM; Schönegg W; Schumacher C; Kutscheidt A; Kiewitz C; Klawitter S; Schmidt M
    Anticancer Res; 2016 Mar; 36(3):967-74. PubMed ID: 26976985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
    Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
    Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
    Zhai X; Hong R; Fan Y; Yuan P; Wang J; Sang D; Chen J; Zhao C; Ou K; Ma F; Xu B
    Thorac Cancer; 2018 May; 9(5):613-620. PubMed ID: 29575760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
    Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.
    Bernardo A; Palumbo R; Pedersini R; Rota Caremoli E; Gambaro AR; Ferzi A; Riva F; Grasso D; Danova M; Tarenzi E; Torri V; Cazzaniga ME
    Clin Breast Cancer; 2017 Oct; 17(6):433-440. PubMed ID: 28366406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
    Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
    Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer.
    Pippen J; Paul D; Vukelja S; Clawson A; Iglesias J
    Breast Cancer Res Treat; 2011 Dec; 130(3):825-31. PubMed ID: 21976055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.
    Müller V; Ruhnke M; Hoffmann O; Grafe A; Tomé O; Fett W; Bruch HR; Sommer-Joos AK; Schneeweiss A
    Breast; 2021 Dec; 60():70-77. PubMed ID: 34488065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
    Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
    Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.